Regeneron Pharmaceuticals Stock Rating Reaffirmed by TheStreet (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating restated by stock analysts at TheStreet in a report issued on Thursday, AnalystRatingsNetwork reports.
The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 145,356 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $302.86, for a total value of $44,022,518.16. Following the sale, the chairman now directly owns 65,759 shares in the company, valued at approximately $19,915,771. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 3.96% during mid-day trading on Thursday, hitting $303.7999. The stock had a trading volume of 294,990 shares. Regeneron Pharmaceuticals has a one year low of $136.13 and a one year high of $311.00. The stock’s 50-day moving average is $262.3 and its 200-day moving average is $239.0. The company has a market cap of $29.681 billion and a price-to-earnings ratio of 38.64.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.73 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.92 by $0.81. The company had revenue of $458.00 million for the quarter, compared to the consensus estimate of $470.63 million. During the same quarter last year, the company posted $0.90 earnings per share. Regeneron Pharmaceuticals’s revenue was up 50.5% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals will post $3.50 EPS for the current fiscal year.
A number of other firms have also recently commented on REGN. Analysts at BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $294.00 to $325.00 in a research note to investors on Tuesday. They now have an “outperform” rating on the stock. Separately, analysts at Goldman Sachs Group Inc. raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $298.00 to $329.00 in a research note to investors on Wednesday, September 18th. Finally, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $286.00 to $293.00 in a research note to investors on Friday, September 13th. They now have an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $267.00.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.